308 related articles for article (PubMed ID: 25592374)
1. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma.
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Van Gele M; van Geel N; Brochez L
J Transl Med; 2015 Jan; 13():9. PubMed ID: 25592374
[TBL] [Abstract][Full Text] [Related]
2. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
Weide B; Martens A; Zelba H; Stutz C; Derhovanessian E; Di Giacomo AM; Maio M; Sucker A; Schilling B; Schadendorf D; Büttner P; Garbe C; Pawelec G
Clin Cancer Res; 2014 Mar; 20(6):1601-9. PubMed ID: 24323899
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer.
Kini Bailur J; Gueckel B; Pawelec G
J Transl Med; 2016 May; 14(1):151. PubMed ID: 27234566
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
[TBL] [Abstract][Full Text] [Related]
7. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.
Jiang H; Gebhardt C; Umansky L; Beckhove P; Schulze TJ; Utikal J; Umansky V
Int J Cancer; 2015 May; 136(10):2352-60. PubMed ID: 25353097
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients.
McCarter MD; Baumgartner J; Escobar GA; Richter D; Lewis K; Robinson W; Wilson C; Palmer BE; Gonzalez R
Ann Surg Oncol; 2007 Oct; 14(10):2854-60. PubMed ID: 17593331
[TBL] [Abstract][Full Text] [Related]
9. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
10. The clinical association of programmed death-1/PD-L1 axis, myeloid derived suppressor cells subsets and regulatory T cells in peripheral blood of stable COPD patients.
Zhang M; Wan Y; Han J; Li J; Gong H; Mu X
PeerJ; 2024; 12():e16988. PubMed ID: 38560459
[TBL] [Abstract][Full Text] [Related]
11. MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation.
Yaddanapudi K; Rendon BE; Lamont G; Kim EJ; Al Rayyan N; Richie J; Albeituni S; Waigel S; Wise A; Mitchell RA
Cancer Immunol Res; 2016 Feb; 4(2):101-12. PubMed ID: 26603621
[TBL] [Abstract][Full Text] [Related]
12. Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma.
Tucci M; Stucci LS; Mannavola F; Passarelli A; D'Oronzo S; Lospalluti L; Giudice G; Silvestris F
Clin Transl Oncol; 2019 Jul; 21(7):845-854. PubMed ID: 30470990
[TBL] [Abstract][Full Text] [Related]
13. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
Idorn M; Køllgaard T; Kongsted P; Sengeløv L; Thor Straten P
Cancer Immunol Immunother; 2014 Nov; 63(11):1177-87. PubMed ID: 25085000
[TBL] [Abstract][Full Text] [Related]
14. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
15. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients.
Choi HS; Ha SY; Kim HM; Ahn SM; Kang MS; Kim KM; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kang ES
Oncotarget; 2016 Feb; 7(7):7940-51. PubMed ID: 26799288
[TBL] [Abstract][Full Text] [Related]
16. Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells.
Hock BD; Mackenzie KA; Cross NB; Taylor KG; Currie MJ; Robinson BA; Simcock JW; McKenzie JL
Nephrol Dial Transplant; 2012 Jan; 27(1):402-10. PubMed ID: 21617199
[TBL] [Abstract][Full Text] [Related]
17. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
18. Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab.
Richez C; Schaeverbeke T; Dumoulin C; Dehais J; Moreau JF; Blanco P
Arthritis Res Ther; 2009; 11(3):R100. PubMed ID: 19563672
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression.
Jin O; Kavikondala S; Sun L; Fu R; Mok MY; Chan A; Yeung J; Lau CS
Lupus; 2008 Jul; 17(7):654-62. PubMed ID: 18625638
[TBL] [Abstract][Full Text] [Related]
20. Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients.
Napolitano M; D'Alterio C; Cardone E; Trotta AM; Pecori B; Rega D; Pace U; Scala D; Scognamiglio G; Tatangelo F; Cacciapuoti C; Pacelli R; Delrio P; Scala S
Oncotarget; 2015 Apr; 6(10):8261-70. PubMed ID: 25823653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
